FINHUB Insights

BMY · Q2 FY25 · Apr 1 – Jun 30, 2025

Bristol Myers Squibb Q2 FY25: where the revenue came from and where it went

Bristol Myers Squibb Q2 FY25: revenue $12.3B (+1% year over year). Net profit $1.3B. Largest cohort International $3.5B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Jul 31, 2025 10-Q
Sankey diagram of Bristol Myers Squibb's income statement for Q2 FY25: revenue of $12.3 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$12.3B +1% year over year
Gross profit$8.9B 73% margin
Operating profit$-0.5B -4% margin
Net profit$1.3B 11% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 12.3 100% +1%
International 3.5 28%
Opdivo 2.6 21%
Other 2.4 20%
Orencia 1 8%
Revlimid 0.8 7% −38%
Yervoy 0.7 6%
Pomalyst/Imnovid 0.7 6% −26%
Reblozyl 0.6 5%
Cost of revenue−3.428%
Gross profit8.973% margin−1pp
Research & development−2.621%−3pp
SG&A−1.714%−2pp
Other−5.141%+0pp
Operating profit-0.5-4% margin+0pp
Tax−0.4
Net profit1.311%−3pp
Filing on EDGAR More quarters of BMY

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters